BioCentury | Mar 15, 2010
Company News

Kyto Biopharma Inc., Research Foundation of the State University of New York deal

...vitamin B12 receptor and is in preclinical testing for cancer. Further details were not disclosed. Kyto Biopharma Inc....
BioCentury | Dec 3, 2007
Company News

Kyto Biopharma Inc. deal

...develop humanized MAbs targeting vitamin B12 receptor to treat cancer. Financial terms were not disclosed. Kyto Biopharma Inc....
BioCentury | Dec 16, 2002
Company News

Kyto Biopharma Inc., Medarex deal

...Prior, Kyto had development and marketing rights to resulting antibodies (see BioCentury, Jan. 29, 2001). Kyto Biopharma Inc....
Items per page:
1 - 3 of 3
BioCentury | Mar 15, 2010
Company News

Kyto Biopharma Inc., Research Foundation of the State University of New York deal

...vitamin B12 receptor and is in preclinical testing for cancer. Further details were not disclosed. Kyto Biopharma Inc....
BioCentury | Dec 3, 2007
Company News

Kyto Biopharma Inc. deal

...develop humanized MAbs targeting vitamin B12 receptor to treat cancer. Financial terms were not disclosed. Kyto Biopharma Inc....
BioCentury | Dec 16, 2002
Company News

Kyto Biopharma Inc., Medarex deal

...Prior, Kyto had development and marketing rights to resulting antibodies (see BioCentury, Jan. 29, 2001). Kyto Biopharma Inc....
Items per page:
1 - 3 of 3